Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages ...

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

Immediate use for the newly developed assembloids could include studying neurodevelopmental disorders such as autism.

Researchers presented a first study on biological pathways perturbed in association with CRCI, anxiety, and co-occurring CRCI.